Cobenfy (xanomeline/trospium) Letter of Medical Necessity
Cobenfy (xanomeline/trospium) represents the first novel mechanism for schizophrenia in decades. Prior auth often requires documentation of atypical antipsychotic failures, particularly for patients with metabolic or movement disorder concerns.
FDA-Approved Indications
- ● schizophrenia
Why Cobenfy Prior Authorization Gets Denied
The most common denial reasons across major payers:
- 1. First-line antipsychotic trial not attempted
- 2. Formulary preferred atypical antipsychotic available
- 3. Inadequate documentation of prior antipsychotic failures or intolerability
- 4. Not yet added to formulary (new-to-market)
What to Include in a Cobenfy Letter of Medical Necessity
Document schizophrenia diagnosis (DSM-5), PANSS or CGI-S scores, prior atypical antipsychotic trials with specific adverse effects (metabolic syndrome, tardive dyskinesia, weight gain), contraindications to dopaminergic agents, and clinical rationale for non-dopaminergic mechanism.
Key clinical evidence to cite:
- ✓ EMERGENT-1 and EMERGENT-2 Phase 3 trials
- ✓ EMERGENT-3 long-term safety data
- ✓ Novel non-dopaminergic mechanism of action
Relevant guidelines:
- 📖 APA Practice Guidelines for Schizophrenia (2020)
- 📖 First non-dopaminergic antipsychotic approved in decades
Cobenfy Prior Authorization Criteria
Standard criteria across major US payers for Cobenfy. Specific criteria vary by plan — RxCheckUp tailors each LMN to your patient's exact payer policy.
Typical step therapy requirements:
- → First-line antipsychotic trial not attempted
- → Inadequate documentation of prior antipsychotic failures or intolerability
Required documentation:
- ✓ ICD-10 diagnosis code with specificity
- ✓ Prior therapy history with dates, doses, and discontinuation reasons
- ✓ Specialist evaluation (where applicable)
- ✓ Baseline disease activity or biomarker results
- ✓ Clinical rationale citing FDA labeling or guidelines
Approval details:
Initial approval: typically 6 months. Renewal: 12 months with documented clinical response.
Payers Covering Cobenfy
RxCheckUp tailors each LMN to the specific payer's medical policy and step therapy requirements:
Cobenfy Prior Authorization FAQ
Why was my Cobenfy prior authorization denied?
The most common denial reasons for Cobenfy are: First-line antipsychotic trial not attempted; Formulary preferred atypical antipsychotic available; Inadequate documentation of prior antipsychotic failures or intolerability; Not yet added to formulary (new-to-market).
What should a Cobenfy Letter of Medical Necessity include?
Document schizophrenia diagnosis (DSM-5), PANSS or CGI-S scores, prior atypical antipsychotic trials with specific adverse effects (metabolic syndrome, tardive dyskinesia, weight gain), contraindications to dopaminergic agents, and clinical rationale for non-dopaminergic mechanism.
Which payers cover Cobenfy?
Cobenfy is covered by major US payers including UnitedHealthcare, Aetna, Cigna, BCBS, Medicaid, though formulary tier and prior authorization criteria vary.